You searched for "consent"
Urinary frequency and COVID-19: is there a missing link?
The current COVID pandemic has been a worldwide challenge for over a year. It can affect an individual in various ways. According to the World Health Organization, the classical signs are dry cough, fever and shortness of breath. In addition,...
Active surveillance for small renal masses in younger patients
Active surveillance (AS) is discussed as an option for renal masses <2cm in patients with significant competing risks for mortality. This multicentre data from the US seeks to fill an important gap in current guidelines for provision of this option...
BCG after TURBT – does timing matter?
Intravesical bacille Calmette–Guerin (BCG) therapy continues to be widely used for patients with intermediate / high-risk non-muscle invasive bladder cancer (NMIBC). In this article, the researchers identified the lack of sufficient evidence with regards to timing of BCG after transurethral...
Save the orchid
In many urological cancers there is currently more and more inclination for organ-preserving surgery but in patients with germ cell tumours (GCT), radical orchidectomy remains the gold standard. Can we somehow save the testes? This study aims to summarise published...
Urology Unboxed: A guide for aspiring urology residents
Urology Unboxed was a delightful read. It is a comprehensive guide for resident and future resident urologists who seek a structured and in-depth insight into common urological presentations. This easy-to follow handbook encompasses everything that a resident surgeon would require...Precision ART: Insights into ICSI and Embryo Biopsy
Course description The microscopic treatment of individual eggs, sperm, or embryos to improve fertilization and pregnancy rates is an essential skill for an embryologist and is critical in achieving the best clinical outcomes. With a focus on ICSI and biopsy...
PARP inhibitors and prostate cancer
The discovery that BRCA1/2-deficient tumour cells are highly sensitive to poly-ADP ribose polymerase (PARP) inhibitors (PARPi) established the foundation of synthetic lethality in metastatic castration-resistant prostate cancer (mCRPC). The TOPARP-A trial confirmed clinical benefit, with PARPi activity largely restricted to...
